Immune checkpoint inhibitor-related cutaneous adverse events

被引：8
|
作者：
He, Chunxia [1 ]
Qu, Tao [1 ]
机构：
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Natl Clin Res Ctr Skin & Immune Dis, Dept Dermatol, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷 / 05期
关键词：
cutaneous toxicities; immune checkpoint inhibitors; immune-related adverse events; outcomes; rechallenge; ASSOCIATION; PEMBROLIZUMAB; IMMUNOTHERAPY; MANAGEMENT; IPILIMUMAB; NIVOLUMAB; VITILIGO;
D O I：
10.1111/ajco.13364
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cutaneous toxicities are the most prevalent immune-related adverse events. Various reactions have been reported. In this review, we summarized the clinicopathologic manifestations, treatment strategies, relevance to tumor outcomes, and rechallenge considerations of cutaneous immune-related adverse events.
引用
收藏
页码：E149 / E153
页数：5
相关论文
共 50 条
  • [41] Immune checkpoint inhibitor-related heart disorders
    [J]. Reactions Weekly, 2021, 1862 (1) : 8 - 8
  • [42] Immune checkpoint inhibitor-related psychiatric disorders
    [J]. Reactions Weekly, 2023, 1957 (1) : 10 - 10
  • [43] Immune checkpoint inhibitor-related aplastic anaemia
    [J]. Reactions Weekly, 2023, 1978 (1) : 3 - 3
  • [44] Characterizing immune checkpoint inhibitor-related cutaneous adverse reactions: A comprehensive analysis of FDA adverse event reporting system (FAERS) database
    Esen, Bugra Han
    Ozbek, Lasin
    Oguz, Sinem
    Selcukbiricik, Fatih
    [J]. HELIYON, 2024, 10 (13)
  • [45] Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma
    Corona-Rodarte, Eduardo
    Olivas-Martinez, Antonio
    Remolina-Bonilla, Yuly A.
    Dominguez-Cherit, Judith G.
    Lam, Elaine T.
    Bourlon, Maria T.
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (10) : 1242 - 1247
  • [46] Immune-related cutaneous adverse events due to checkpoint inhibitors
    Wang, Evelyn
    Kraehenbuehl, Lukas
    Ketosugbo, Kwami
    Kern, Jeffrey A.
    Lacouture, Mario E.
    Leung, Donald Y. M.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 126 (06) : 613 - 622
  • [47] Checkpoint inhibitor associated bullous cutaneous adverse immune-related events: a multicentre observational study
    Kawsar, Anusuya
    Edwards, Charlotte
    Harwood, Catherine A.
    Matin, Rubeta
    Lorigan, Paul
    Harland, Chris
    Patel, Pooja
    Heywood, Richard
    Gupta, Aakrati
    Mann, Jasmine
    Heelan, Kara
    Larkin, James
    Fearfield, Louise
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 18 - 18
  • [48] Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
    Coukos, Alexander
    Vionnet, Julien
    Obeid, Michel
    Bouchaab, Hasna
    Peters, Solange
    Latifyan, Sofiya
    Wicky, Alexandre
    Michielin, Olivier
    Chtioui, Haithem
    Moradpour, Darius
    Fasquelle, Francois
    Sempoux, Christine
    Fraga, Montserrat
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
  • [49] Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy
    Ho, Adrienne K.
    Ho, Anthony M-H
    Cooksley, Tim
    Nguyen, Giang
    Erb, Jason
    Mizubuti, Glenio B.
    [J]. ANESTHESIA AND ANALGESIA, 2021, 132 (02): : 374 - 383
  • [50] Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis
    Xiao-Tong Zhang
    Nan Ge
    Zi-Jian Xiang
    Tao Liu
    [J]. Cancer Cell International, 22
12345